OS Therapies Incorporated Common Stock (NY:OSTX)

1.620 +0.010 (+0.62%)

Official Closing Price Updated: 8:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about OS Therapies Incorporated Common Stock

< Previous 1 2 3 4 5 Next >

OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans

April 10, 2025

Yet to be published data from clinical study combining OST-HER2 with palliative radiation in dogs with unresected, primary osteosarcoma shows...

Via Newsfile

OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals

April 09, 2025

From OS Therapies

Via Business Wire

OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma

April 07, 2025

From OS Therapies

Via Business Wire

OS Therapies to Host Analyst Day at NYSE on April 7, 2025

April 02, 2025

From OS Therapies

Via Business Wire

OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update

March 31, 2025

From OS Therapies Inc.

Via Business Wire

OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma

March 31, 2025

From OS Therapies

Via Business Wire

OS Therapies’ OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers

March 25, 2025

From OS Therapies

Via Business Wire

OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference

March 21, 2025

From OS Therapies

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

March 20, 2025

Via Benzinga

OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference

March 13, 2025

From OS Therapies, Inc.

Via Business Wire

OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma

March 11, 2025

From OS Therapies, Inc.

Via Business Wire

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) and OS Therapies (NYSE American: OSTX) to Appear on RedChip’s Bloomberg TV Show

February 28, 2025

Via Investor Brand Network

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

February 28, 2025

Via ACCESS Newswire

Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27

February 26, 2025

From OS Therapies

Via Business Wire

OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms

February 24, 2025

From OS Therapies, Inc.

Via Business Wire

OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2

February 20, 2025

From OS Therapies, Inc.

Via Business Wire

Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins

February 18, 2025

Vancouver, BC – February 18, 2025 – USA News Group News Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI data centers), there is still cause for...

Via FinancialNewsMedia

Topics Artificial Intelligence

Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer ↗

February 14, 2025

OS Therapies advances OST-HER2, a HER2-targeted immunotherapy, with plans for FDA submission following promising Phase 2b data in osteosarcoma.

Via Benzinga

Friday's session: gap up and gap down stocks ↗

February 14, 2025

The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Via Chartmill

Top movers in Friday's pre-market session ↗

February 14, 2025

Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing

February 14, 2025

From OS Therapies, Inc.

Via Business Wire

OS Therapies Provides Corporate Update

February 04, 2025

From OS Therapies, Inc.

Via Business Wire

RedChip Launches RedChat: Revolutionary AI Chatbot for Small-Cap Stock Analysis

February 03, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 31, 2025

Via Benzinga

OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline

January 29, 2025

From OS Therapies

Via Business Wire

Kairos, OS Therapies, AEON See Highest Weekly Spike In Retail Following Among Biotechs: Here's Why ↗

January 21, 2025

Cancer treatments, FDA breakthroughs, and other developments fueled a sharp spike in interest for these biotech players, as investors bet on promising clinical data and strategic moves.

Via Stocktwits

Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday? ↗

January 15, 2025

OS Therapies shares Phase 2b trial results showing OST-HER2 improves survival rates in rare metastatic osteosarcoma, surpassing historical controls.

Via Benzinga

OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma

January 15, 2025

From OS Therapies, Inc.

Via Business Wire

OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference

January 02, 2025

From OS Therapies, Inc.

Via Business Wire

OS Therapies Announces Closing of $6 Million Private Placement

December 31, 2024

From OS Therapies, Inc.

Via Business Wire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.